This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Universitätsmedizin Der Johannes Gutenberg-Universitat Mainz. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Nikola Gaidzik: Innovator in Cancer Detection and Treatment
Introduction
Nikola Gaidzik is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of cancer research through his innovative work on peptide-based compounds. His dedication to advancing medical science is reflected in his patent, which focuses on the prevention, treatment, and detection of cancer.
Latest Patents
Nikola Gaidzik holds a patent for peptide-based compounds designed for use in the prevention, treatment, and/or detection of cancer. The patent describes a compound that includes a first polypeptide sequence with at least three different amino acid sequences selected from specific groups. Additionally, it features a second polypeptide sequence with its own set of amino acid sequences. This compound is capable of binding to tumor-associated Mucin-1 (TA-MUC1), which is crucial for cancer research and therapy. He has 1 patent to his name.
Career Highlights
Throughout his career, Nikola Gaidzik has worked with prestigious institutions, including Universitätsmedizin der Johannes Gutenberg-Universität Mainz and Johannes Gutenberg-Universität Mainz. His work in these organizations has allowed him to collaborate with leading experts in the field of medical research.
Collaborations
Some of Nikola Gaidzik's notable coworkers include Edgar Schmitt and Horst Kunz. Their collaborative efforts have contributed to advancements in cancer research and the development of innovative therapeutic strategies.
Conclusion
Nikola Gaidzik's contributions to cancer research through his patented innovations highlight his commitment to improving medical outcomes. His work exemplifies the importance of innovation in the fight against cancer.